anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Microvascular obstruction (MVO) and intramyocardial hemorrhage (IMH) are well-established imaging biomarkers of failed myocardial tissue reperfusion in patients with ST-segment elevation-myocardial infarction treated with percutaneous coronary intervention. MVO and IMH are associated with an increased risk of adverse outcome independent of infarct size, but whether the size of the culprit lesion vessel plays a role in the occurrence and severity of reperfusion injury is currently unknown. This study aimed to evaluate the association between culprit lesion vessel size and the occurrence and severity of reperfusion injury as determined by cardiac magnetic resonance imaging.
METHODS AND RESULTS: Patients (n=516) with first-time ST-segment-elevation myocardial infarction underwent evaluation with cardiac magnetic resonance at 4 (3-5) days after infarction. MVO was assessed with late gadolinium enhancement imaging and IMH with T2* mapping. Vessel dimensions were determined using catheter-based reference. Median culprit lesion vessel size was 3.1 (2.7-3.6) mm. MVO and IMH were found in 299 (58%) and 182 (35%) patients. Culprit lesion vessel size was associated with body surface area, diabetes, total ischemic time, postinterventional thrombolysis in myocardial infarction flow, and infarct size. There was no association between vessel size and MVO or IMH in univariable and multivariable analysis (P>0.05). These findings were consistent across patient subgroups with left anterior descending artery and non-left anterior descending artery infarctions and those with thrombolysis in myocardial infarction 3 flow post-percutaneous coronary intervention.
CONCLUSIONS: Comprehensive characterization of myocardial tissue reperfusion injury by cardiac magnetic resonance revealed no association between culprit lesion vessel size and the occurrence of MVO and IMH in patients treated with primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction.
An antiproliferative peptides containing the amino acid sequence (I) or a hydropathically homologous sequence, is new. An antiproliferative peptides containing the amino acid sequence (I) Lys-Arg-Lys-Arg-Ser-Pro-Val-Arg-Ser-Leu-Phe-Tyr-Lys-Lys-Val-Tyr-Arg-L eu-Ala-Pro-Lys-Thr or a hydropathically homologous sequence, is new. Independent claims are also included for the following: (1) Nucleic acids coding for the novel peptide; and (2) peptide nucleic acids with a homologous structure to the nucleic acids of (1). - ACTIVITY : Cytostatic; Antiarteriosclerotic; Antipsoriatic. No biological data is given. - MECHANISM OF ACTION : Gene therapy.
Mid-aortic syndrome (MAS) is a rare vascular disease that usually leads to renovascular hypertension. With the predominant manifestations being intractable arterial hypertension and lower extremity arterial insufficiency, it has rarely been associated with dilated cardiomyopathy. We report a young girl with congestive heart failure, where the cause was initially attributed to dilated cardiomyopathy. A repeated echocardiogram 6 months later brought the physician's suspicion of MAS because of the abnormal colour of Doppler from the subcostal view. Further assessment using CT angiography revealed discrete thoracic coarctation at the level of T10, with the narrowest diameter of 2.1 mm, thus confirming the diagnosis. Her inflammatory markers and connective tissue screening were negative. She underwent successful stenting of coarctation of the aorta, which later caused improvement in her cardiac function. We highlighted the importance of looking for treatable causes of dilated cardiomyopathy and vigilant clinical and echocardiogram assessment with high suspicion to diagnose MAS.
A moulding composition comprises 1,8 to 2,6 parts by weight of finely divided solid polymethyl methacrylate to 1 part by weight of liquid methyl methacrylate monomer and, as cross-linking agent, from 2 to 20% by weight of a polyfunctional polymerizable monomer, e.g. allyl methacrylate, methallyl methacrylate, ethylene dimethacrylate, ethylene glycol dimethacrylate, or a polyethylene glycol dimethacrylate.  In an example, the following composition is used: polymethyl methacrylate 2,4 parts, methyl methacrylate monomer 1 part, benzoyl peroxide 0,02 part and ethylene glycol dimethacrylate 0,30 part.  U.S.A. Specification 2,409,783 is referred to.ALSO:Moulded composite articles, e.g. artificial teeth and dentures, plastic inlays and plastic jewellery, of polymethyl methacrylate resin are formed by shaping a first dough portion from a dough of mixed finely divided solid polymethyl methacrylate and liquid methyl methacrylate monomer with from 2 to 20% by weight of a polyfunctional polymerizable monomer, e.g. allyl methacrylate, methallyl methacrylate, ethylene dimethacrylate or a polyethylene glycol dimethacrylate, as cross-linking agent, while simultaneously contacting one surface with a heat-resistant non-adherent liner sheet linear polyethylene, polytetrafluoroethylene, polyvinyl alcohol or heat-resistant nylon having a thickness of from 1 to 10 mils, polymerizing this first dough portion by moulding it faced with the liner sheet at elevated temperature and pressure to substantially the same shape p  as it will have in the composite article, an incompletely polymerized latent adhesive surface portion being formed under the liner sheet, removing the liner sheet, assembling against the latent adhesive surface portion a second dough portion of the same composition as the first and moulding the two dough portions at elevated temperature and pressure to polymerize the second dough portion and the incompletely polymerized surface portion of the first dough portion while bonding the latter with the contacting surface of the second dough portion.  The invention is described with particular reference to the manufacture of a composite artificial tooth utilizing a multi-part separable mould in one part of which is moulded the first dough portion to form the lingual portion of the tooth and in a second portion of which is moulded the second dough portion to form the labial portion of the tooth.  U.S.A. Specification 2,409,783 is referred to.
* Therapy with ZOMACTON should be supervised by a physician who is experienced in the diagnosis and management of patients with the conditions for which ZOMACTON is indicated [see Indications and Usage (1)].
  * Fundoscopic examination should be performed routinely before initiating treatment with ZOMACTON to exclude preexisting papilledema, and periodically thereafter [see Warnings and Precautions (5.5)].
  * Administer ZOMACTON by subcutaneous injection to the back of the upper arm, abdomen, buttock, or thigh with regular rotation of injection sites to avoid lipoatrophy.
  * ZOMACTON 5 mg and 10 mg can be administered using a standard sterile disposable syringe. For proper use, please refer to the Instructions for Use provided with the administration device. The volume of the syringe should be small enough so that the prescribed dose can be withdrawn from the vial with reasonable accuracy.
Image-guided navigation surgery allows for full utilization of pre-operative imaging during surgery and has the potential of reducing both irradical resections and morbidity. To use navigation, a registration procedure is required to correlate pre-operative imaging with the patient's position on the operating room (OR). Currently, registration is done by Cone-Beam CT (CBCT) scanning on the OR prior to navigation surgery. However, the main limitation of the CBCT method is that it cannot compensate for per-operative changes such as bed rotation, retractor placement and tissue displacement due to the surgery. Alternatively, by using intra-operative tracked ultrasound and vessel-based patient registration, changing conditions during surgery can better be dealt with. This improved patient registration method could lead to an increased navigation accuracy and improved clinical usability and outcomes.

The main difference between CBCT and proposed ultrasound registration is that CBCT is based on bones, while the ultrasound is based on vessels. Bones can be very easily imaged on the CBCT and therefore used for bone-bone registration with pre-operative CT-scans. However, vessels are more difficult to acquire, especially with ultrasound, and an automatic registration process with pre-operative imaging is needed for efficient clinical usability. For this, the vessels need to be extracted from the tracked ultrasound images to create a 3D representation that can be registered. Therefore, an algorithm needs to be developed that can automatically segment the pelvic vessels from ultrasound images.
PROBLEM TO BE SOLVED: To obtain the subject material having excellent surface appearance of molding product and excellent mechanical characteristics by making the material include a polycarbonate resin and an aluminum borate whisker whose surface is coated with an epoxy resin urethane prepolymer reaction product in a specific ratio. SOLUTION: This material comprises (A) 100 pts.wt. of a polycarbonate resin and (B) 5-45 pts.wt. of (ii) an aluminum borate whisker whose surface is coated with (i) an epoxy resin urethane prepolymer reaction product such as a compound of formula I [X is a group of formula II (l is 20,000>=l>=0; m is 20,000>=m>=10); n is 20,000>=n>=1]. Preferably the amount of the component (i) applied to the component ii is 0.05-20 pts.wt. based on 100 pts.wt. of the component ii. A method for dispersing the component ii into a solvent in which the component (i) is soluble, then adding the component (i), subjecting the dispersion to solid-liquid separation and drying may be cited as the coating method.
AIMS: Esketamine may reduce acute postoperative pain in several settings. However, the effects of low-dose esketamine on postoperative pain after vestibular schwannoma (VS) resection with propofol/remifentanil total intravenous anaesthesia (TIVA) are unclear. The aim of this study is to observe the effects of intraoperative low-dose esketamine on postoperative pain after vestibular schwannoma resection.
METHODS: This single-centre, randomized, placebo-controlled, double-blind trial included 90 adults undergoing VS resection via the retrosigmoid approach with TIVA. The patients were randomly allocated to two groups: esketamine or control (n = 45 in each group). Patients received low-dose esketamine (0.2 mg/kg) or a similar volume of normal saline after dural closure. The primary outcome was the pain score during movement (gentle head movement) at 24 h postoperatively. Secondary outcomes included recovery time, bispectral index (BIS) values and haemodynamic profiles during the first 30 min after esketamine administration, and adverse effects.
RESULTS: Low-dose esketamine did not reduce pain scores at rest (P > .05) or with movement (P > .05) within the first 24 h after surgery. Esketamine moderately increased BIS values for at least 30 min after administration (P < .0001) but did not affect heart rate (P = .992) or mean arterial blood pressure (P = .994). Esketamine prolonged extubation time (P = .042, 95% confidence interval: 0.08 to 4.42) and decreased the effect-site concentration of remifentanil at extubation (P = .001, 95% confidence interval: -0.53 to -0.15) but did not affect the time to resumption of spatial orientation. Postoperative nausea and vomiting rates did not differ between groups, and no hallucinations or excessive sedation was observed.
CONCLUSION: Intraoperative low-dose esketamine did not significantly reduce acute pain after VS resection with propofol/remifentanil TIVA. However, BIS values increased for at least 30 min after esketamine administration.
Patients receive irinotecan IV over 90 minutes immediately followed by docetaxel IV over 60 minutes on day 1. Treatment is repeated every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 5 years or until death.
Disclosed is the composition for treating or curing diabetes mellitus containing an ingredient or component suitable for treatment of diabetes mellitus from an extract obtained by immersing a plant belonging to genus Tithonia and/or Ludwigia in a pharmacologically acceptable solvent for a predetermined period of time, said plant belonging to genus Tithonia being Tithonia diversifolia (Hemsl.) A. Gray, Tithonia rotundifolia (Mill) Blake, Tithonia fruticosa Canby & Rose, Tithonia scaberrima Benth. or Tithonia longeradiata (Bertol) Brake; and said plant belonging to genus Ludwigia being Ludwigia octovalvis Raven or Ludwigia prostrata Roxb. or Ludwigia epilobioides Maxim. The composition administered in the form of tea or drink or other formulation to a diabetic patient by first applying a composition containing an extract from the plant belonging to genus Tithonia and thereafter applying a composition containing an extract from the plant belonging to genus Ludwigia. The composition for treating diabetes mellitus can alleviate or diminish a variety of symptoms caused by diabetes mellitus or prevailing among diabetic patients, thereby naturally reducing or lowering blood glucose levels to a normal range and preventing diabetes mellitus to be caused to reoccur for a long period of time without continuously administering the composition.
FIELD: medicinal microbiology, selection of bacterial strains. SUBSTANCE: method involves selection of subculture showing phenotype Cap-Tox- and genotype pXO1 among population strains exhibiting decreased virulence. This subculture is passaged through organism of white mongrel mice. Method can be used as a test for reversion to high virulence for evaluation of epidemic significance of natural isolates. EFFECT: increased virulence of anthrax microbe. 1 dwg, 1 tbl
Glioma is a medical term that describes a tumor originating in the brain. Several risk factors could develop glioma such as occupational exposure, gene mutation and ionizing radiation. Therefore, we aim to determine the expression and biological function of interleukin 37 (IL-37) in gliomas with different pathological grades. We used 95 participants with different pathological grades of glioma as our data subjects. We used CCK-8 assay and transwell assay to explore the proliferation of U251 over-expressing IL-37 and migration and invasion of U251. We found that IL-37 expression in tumor tissues was significantly higher than in normal tissue. The reduced IL-37 expression in gliomas was significantly associated with a higher WHO grade and lower Karnofsky Performance Status score. IL-37 expression in glioma tissues showed a decline with the increase of the WHO glioma grade. Patients with low IL-37 expression showed a shorter median survival. Transwell assay indicated that migration and invasion of U251 over-expressing IL-37 was significantly lower than that of the control at 24 h. Our findings showed that low IL-37 expression was negatively correlated with pathological grade and was positively correlated with survival time.
All patients were treated with imatinib mesylate at a target dose of 400 mg daily by mouth for 12 months. Dose modifications and interruptions were made for AE and were recorded. After 12 months of treatment, imatinib was stopped for 3 months. Patients were reassessed and offered entrance to an extension phase of the trial.
AIM: We aimed to explore whether the combination of CLP290 and bumetanide maximally improves neuropathic pain following spinal cord injury (SCI) and its possible molecular mechanism.
METHODS: Rats were randomly divided into five groups: Sham, SCI + vehicle, SCI + CLP290, SCI + bumetanide, and SCI + combination (CLP290 + bumetanide). Drug administration commenced on the 7th day post-injury (7 dpi) and continued for 14 days. All rats underwent behavioral assessments for 56 days to comprehensively evaluate the effects of interventions on mechanical pain, thermal pain, cold pain, motor function, and other relevant parameters. Electrophysiological assessments, immunoblotting, and immunofluorescence detection were performed at different timepoints post-injury, with a specific focus on the expression and changes of KCC2 and NKCC1 proteins in the lumbar enlargement of the spinal cord.
RESULTS: CLP290 and bumetanide alleviated SCI-associated hypersensitivity and locomotor function, with the combination providing enhanced recovery. The combined treatment group exhibited the most significant improvement in restoring Rate-Dependent Depression (RDD) levels. In the combined treatment group and the two individual drug administration groups, the upregulation of potassium chloride cotransporter 2 (K+-Cl-cotransporter 2, KCC2) expression and downregulation of sodium potassium chloride cotransporter 1 (Na+-K+-Cl-cotransporter 1, NKCC1) expression in the lumbar enlargement area resulted in a significant increase in the KCC2/NKCC1 ratio compared to the SCI + vehicle group, with the most pronounced improvement seen in the combined treatment group. Compared to the SCI + vehicle group, the SCI + bumetanide group showed no significant paw withdrawal thermal latency (PWTL) improvement at 21 and 35 dpi, but a notable enhancement at 56 dpi. In contrast, the SCI + CLP290 group significantly improved PWTL at 21 days, with non-significant changes at 35 and 56 days. At 21 dpi, KCC2 expression was marginally higher in monotherapy groups versus SCI + vehicle, but not significantly. At 56 dpi, only the SCI + bumetanide group showed a significant difference in KCC2 expression compared to the control group.
CONCLUSION: Combined application of CLP290 and bumetanide effectively increases the ratio of KCC2/NKCC1, restores RDD levels, enhances GABAA receptor-mediated inhibitory function in the spinal cord, and relieves neuropathic pain in SCI; Bumetanide significantly improves neuropathic pain in the long term, whereas CLP290 demonstrates a notable short-term effect.
This is a 26-week randomized, double-blind, parallel group prospective study of the effectiveness of treating insulin resistance (IR) to improve mood in patients with IR and treatment-resistant bipolar depression (TRBD). The investigators will compare the effects of treating IR (with metformin) versus placebo on outcome in each patient. The primary outcome will be change in Montgomery-Ǻsberg Depression Rating Scale (MADRS) scores. Patients' current optimized mood stabilizing treatment as usual (TAU, according to the Canadian Network for Mood and Anxiety Treatments \[CANMAT\] or American Psychiatric Association \[APA\] guidelines) must remain unchanged for a period of at least 4 weeks prior to and throughout the study. Patients will undergo a baseline assessment and then be randomized to treatment with metformin or placebo with titration to full dose after 2 weeks. Patients will remain on full treatment for 24 weeks thereafter (total trial duration of 26 weeks for each patient). In those patients with TRBD assigned to treatment with the insulin sensitizer metformin, a significant improvement in depression symptoms will be mediated by the conversion of IR to insulin sensitivity.

Subjects: We aim to enrol 110 subjects with IR and TRBD from 2 sites: the primary site in Halifax, Nova Scotia, Canada, and a second site in Pittsburgh, Pennsylvania, USA.
It is well known that participation in sports activities as a youth has several health benefits, but at the same time, studies report that the risk is high to obtain injuries related to participation. There is, however, increasing evidence that many of these injuries can be prevented if necessary measures are taken. So far, most studies examining sports injuries have been conducted on adult elite and among team sports, for example football, ice hockey and bandy. How injury patterns present in individual sports and among youth is not as well documented. A major problem in athletics is that studies have shown an almost identical prevalence and incidence of injury associated with athletics among both young and adult athletes.

Today there are very few published studies on international incidence of injuries among adolescent athletes in athletics and no describing the incidence in Swedish Athletics. These studies have different study design, definitions of injury and rather small groups of athletes, making it difficult to draw conclusions that can be the basis for prevention programs. What after all can be inferred from these previous studies is that injuries related to overuse seems to be most prevalent. Prospective studies are therefore needed to be able to plan and carry out measures to prevent the occurrence of injuries. We intend to carry out an intervention study among athletics youths aged 12-15 years. Before this is carried out, the investigators need to have adequate knowledge of the study population for the effective implementation of the intervention study.

The overall aim of the project KLUB is to study the prevalence and incidence of injuries among athletics youths aged 12-15 years. A particular focus will be placed on identifying factors associated with injury occurrence. The knowledge obtained will be used to allow for injury prevention in the future.
INTRODUCTION: Agitation, psychosis, and apathy are prevalent and highly distressing neuropsychiatric symptoms (NPS) of Alzheimer's disease (AD) that have been linked to numerous negative outcomes, including increased mortality, worsened cognitive decline, and caregiver burden. Current treatments for AD-associated agitation, namely atypical antipsychotics, provide some benefits but may increase the risk of serious adverse events and death. Meanwhile, no pharmacotherapies have been approved by regulatory agencies for the treatment of psychosis or apathy in AD. Over the past decade, many new and repurposed drugs have emerged as potential therapeutic options for managing these challenging NPS.
AREAS COVERED: This review aims to provide a comprehensive summary of pharmacotherapies that have recently been investigated in phase 2 and 3 clinical trials for the treatment of agitation, psychosis, or apathy in AD.
EXPERT OPINION: Novel atypical antipsychotics, serotonergic antidepressants, cannabinoids, and dextromethorphan combination drugs have shown promising results for alleviating agitation. Pimavanserin appears to be the most effective emerging therapy for psychosis, while methylphenidate has demonstrated good efficacy for apathy. Further research on biomarkers of NPS severity and treatment response, as well as continued improvements in methodological approaches are needed to advance the field.
No intervention will be applied to the control group of 25 people. Pre-test, post-test and follow-up test will be applied.
Nonalcoholic fatty liver disease (NAFLD) represents the most prevalent type of chronic liver disease, spanning from simple steatosis to nonalcoholic steatohepatitis (NASH). Corn oligopeptide (CP) is a functional peptide known for its diverse pharmacological effects on metabolism. In this study, we evaluated the protective activity of CP against fatty liver disease. Oral administration of CP significantly reduced body weight gain by 2.95%, serum cholesterol by 22.54%, and liver injury, as evidenced by a reduction of 32.19% in serum aspartate aminotransferase (AST) and 49.10% in alanine aminotransferase (ALT) levels in mice subjected to a high-fat diet (HFD). In a streptozotocin/HFD-induced NASH mouse model, CP attenuated body weight gain by 5.11%, liver injury (with a 34.15% decrease in AST and 11.43% decrease in ALT), and, to some extent, liver inflammation and fibrosis. Proteomic analysis revealed the modulation of oxidative phosphorylation and sirtuin (SIRT) signaling pathways by CP. Remarkably, CP selectively inhibited the hepatic expression of mitochondrial SIRT3 and SIRT5 in both HFD and NASH models. In summary, CP demonstrates a preventive effect against metabolic-stress-induced NAFLD progression by modulating oxidative stress and the SIRT signaling pathway, suggesting the potential of CP as a therapeutic agent for the treatment of NAFLD and advanced-stage NASH.
Solar lentigines on the left back of the hand side are treated with Pigmanorm Cream once a day for 7 weeks. Solar lentigines on the right back of the hand side are treated with a Q-switched Ruby laser at Baseline and if required at day 28.